Pharmaceutical
Upcoming Earnings
Biopharmaceutical

Bristol-Myers Squibb

$43.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.28 (0.65%) Today
-$0.01 (-0.02%) As of 7:51 PM EDT after-hours

Why Robinhood?

You can buy or sell BMY and other stocks, options, ETFs, and crypto commission-free!

About BMY

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. Read More The company was founded in August 1933 and is headquartered in New York, NY.

Employees
23,300
Headquarters
New York, New York
Founded
1933
Market Cap
69.96B
Price-Earnings Ratio
13.52
Dividend Yield
3.10
Average Volume
12.47M
High Today
$43.07
Low Today
$42.48
Open Price
$42.81
Volume
17.66M
52 Week High
$63.69
52 Week Low
$42.48

Collections

Pharmaceutical
Upcoming Earnings
Biopharmaceutical
Manufacturing
Research And Development
Health
Biotechnology
Technology

BMY News

BenzingaJul 19

Top 5 Vendors in the Global Non-small Cell Lung Cancer Drugs Market 2019-2023 | Technavio

171
Yahoo FinanceJun 25

Company News For Jun 25, 2019

1,244
FortuneJun 24

Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health

2,112

BMY Earnings

$0.67
$0.81
$0.96
$1.10
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
$1.06 per share
Actual
Available Jul 25, Pre-Market

Popular Stocks

More BMY News

Yahoo FinanceJun 24

Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative

231
Washington PostJun 24

Bristol-Myers’s $74 Billion Celgene Splurge Just Got Riskier

623
ReutersJun 24

Bristol-Myers plans to divest Celgene's psoriasis drug

293
MarketWatchJun 24

Bristol-Myers to shed psoriasis drug to win approval for Celgene deal

14
Barron'sJun 24

Bristol-Myers Squibb Stock Is Falling as Celgene Deal Is Delayed

554
MarketWatchJun 24

UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal

445
Washington PostJun 24

US stock indexes edge mostly lower ahead of trade talks

5
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.